What Statins Can’t Achieve: Failed AURORA Study Reinforces ESRD Doubts
It was foregone that the AURORA trial testing rosuvastatin in patients with advanced kidney disease on dialysis didn't work out; AstraZeneca noted it would no longer pursue the project during its 2008 year-end earnings call Jan. 28
You may also be interested in...
The agency's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Nov. 2 to discuss whether the SHARP study results support use of the cholesterol-lowering agents for cardiovascular risk reduction in patients with renal disease.
A few months after the release of AstraZeneca's widely heralded JUPITER Crestor study, physicians seem prepared to prescribe statins more broadly based on that evidence, according to discussion at the American College of Cardiology annual meeting
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.